Table 2.

Prespecified adverse event preferred terms, MedDRA version 12.1

Ocular	Nonocular
Endophthalmitis	Drug hypersensitivity
Panophthalmitis	Hypersensitivity
Intraocular pressure, increased	Hypersensitivity NOS (v. 5.1)
Ocular hypertension	Anaphylactic shock
Glaucoma	Anaphylactic reaction
Glaucoma NOS (v. 5.1)	Anaphylactoid shock
Glaucoma, traumatic	Anaphylactoid reaction
Retinal injury	Angioedema
Retinal tear	Angioneurotic edema (v. 5.1)
Retinal detachment	Blepharitis, allergic
Retinal hemorrhage	Dermatitis, contact
Retinal toxicity	Dermatitis, allergic
Detachment of retinal pigment epithelium	Toxic skin eruption
Retinal pigment epitheliopathy (v. 5.1)	Toxic epidermal necrolysis
Eye hemorrhage	Lyell syndrome (v. 5.1)
Eye hemorrhage NOS (v. 5.1)	Drug eruption
Vitreous hemorrhage	Dermatitis medicamentosa (v. 5.1)
Cataract traumatic	Erythema
Erythema multiforme	Urticaria
Tongue edema	Stevens-Johnson syndrome
Pharyngeal edema	Stevens-Johnson syndrome (v. 5.1)
Laryngeal edema	Rash
Latex allergy	Rash NOS (v. 5.1)
Paresthesia oral	Skin reaction
Paraesthesia mucosal	Acute generalized exanthematous pustulosis
Paraesthesia mucosal NOS (v. 5.1)	Drug rash with eosinophilia and systemic symptoms
Antiplatelet Trialists’ Collaboration Events
Cardiovascular	Cerebrovascular
Acute myocardial infarction	Brain stem infarction
Cardiac arrest	Cerebrovascular accident
Cardiac failure congestive	Lacunar infarction
Myocardial infarction	Cerebral hemorrhage
Retroperitoneal hemorrhage	Transient ischemic attack
Sudden death	Peripheral vascular thrombosis
Silent myocardial infarction	Pulmonary embolism
Coronary artery stenosis	Deep vein thrombosis
Acute coronary syndrome	Thrombosis
Angina pectoris	Ischemia
Angina unstable	Ischemia NOS (v. 5.1)

MedDRA: Medical Dictionary for Regulatory Activities.

NOS: not otherwise specified.

V: version.